Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.

Judo Bio’s leadership team, board of directors, and advisors bring unparalleled knowledge of oligonucleotide therapies and a proven track record of discovering and developing transformative therapies.

Oct 7, 2024 · Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases.

Oct 7, 2024 · Judo has wrapped up preclinical studies showing receptor-mediated oligonucleotide delivery to the kidney with ligand-siRNA conjugates that silence several target genes, according to the company.

Oct 7, 2024 · A new biotechnology company called Judo Bio is taking a strike at kidney diseases, armed with $100 million and a RNA drug platform it claims can get to targets that historically have been challenging for researchers to hit.

Oct 8, 2024 · Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases.

Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients …

Oct 7, 2024 · Judo Bio, a startup focused on developing oligonucleotide-based silent RNA (siRNA) treatments for systemic and renal diseases is emerging from stealth mode today, launching with $100 million in...

Oct 7, 2024 · Judo Bio debuted Monday after about 3 years in stealth. The company has designed a drug candidate that combines a ligand with small interfering RNA (siRNA) that should silence messenger RNA (mRNA) and, in turn, reduce certain solute carrier proteins that are involved in disease.

Oct 8, 2024 · Genetic medicine startup Judo Bio has launched with $100 million in financing, combining its seed funding and a Series A round. The funding will be used to advance the development of oligonucleotide therapies for multiple systemic diseases, delivered via the kidney.